Epicure: efficacy of nintedanib as a treatment for epistaxis in HHT disease. A national, randomized, multicenter phase II study

被引：0

作者：

Hermann, R. ^{[1
]}

Fargeton, A. ^{[2
,3
]}

Decullier, E. ^{[4
]}

Chinet, T. ^{[5
]}

Corre, R. ^{[6
]}

Gilbert-Dussardier, B. ^{[7
]}

Grobost, V ^{[8
]}

Hatron, P. ^{[9
]}

Lavigne, C. ^{[10
]}

Leguy-Seguin, V ^{[11
]}

Parrot, A. ^{[12
]}

Riviere, S. ^{[13
]}

Seguier, J. ^{[14
]}

Beaudoin, M. ^{[2
,3
]}

Roux, A. ^{[4
]}

Bel, F. ^{[15
]}

Gervaise, C. ^{[15
]}

Faure, F. ^{[1
]}

Dupuis-Girod, S. ^{[2
,3
]}

机构：

[1] Hop Edouard Herriot, HCL, Serv ORL, Lyon, France

[2] Hop Femme Mere Enfant, HCL, Serv Genet, Bron, France

[3] Hop Femme Mere Enfant, HCL, Ctr Reference Malad Rendu Osler, Bron, France

[4] HCL, Unite Rech Clin, Pole Sante Publ, Lyon, France

[5] Hop Ambroise Pare, Serv Radiol & Pneumol Intervent, Boulogne Billancourt, France

[6] Hop Pontchaillou, Serv Pneumol, Rennes, France

[7] Hop J Bernard, Serv Genet, Poitiers, France

[8] CHU Estaing, Serv Med Interne, Clermont Ferrand, France

[9] Hop Jeanne de Flandre, Serv Med Interne, Lille, France

[10] CHU Angers, Serv Med Interne, Angers, France

[11] Hop Bocage, Serv Med Interne, Dijon, France

[12] Hop Tenon, Serv Imagerie & Radiol Intervent, Paris, France

[13] Hop St Eloi, Serv Med Interne, Montpellier, France

[14] Hop La Timone, Serv Med Interne, Marseille, France

[15] Grp Hosp Est, HCL, Pharm, Bron, France

来源：

ANGIOGENESIS | 2019年 / 22卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：629 / 630

页数：2

共 50 条

[1] Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial
Hermann, Ruben
Grobost, Vincent
Le-Guillou, Xavier
Lavigne, Christian
Parrot, Antoine
Riviere, Sophie
Seguier, Julie
Fargeton, Anne-Emmanuelle
de-Montigny, Aurelie
Huot, Margaux
Decullier, Evelyne
Roux, Adeline
Gervaise, Caroline
Cartier, Cesar
Dufour, Xavier
Grall, Margaux
Jegoux, Frank
Laccourreye, Laurent
Michel, Justin
Saroul, Nicolas
Wagner, Isabelle
Kerjouan, Mallorie
Dupuis-Girod, Sophie
ANGIOGENESIS, 2025, 28 (01)
[2] Tacro study: efficacy and safety of a 0.1% tacrolimus nasal ointment as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). A double-blind, randomized, placebo-controlled, multicenter trial
Hermann, R.
Fargeton, A.
Grobost, V
Riviere, S.
Decullier, E.
Saroul, N.
Cartier, C.
Philouze, P.
Roux, A.
Breant, V
Colombet, B.
Beaudoin, M.
Faure, F.
Dupuis-Girod, S.
ANGIOGENESIS, 2019, 22 (04) : 594 - 594
[3] Tempo: efficacy of a timolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). Randomized trial against placebo
Fargeton, A-E
Letievant, J. C.
Faure, F.
Bergerot, C.
Decullier, E.
Bin, S.
Breant, V
Collombet, B.
Dupuis-Girod, S.
ANGIOGENESIS, 2015, 18 (04) : 555 - 555
[4] Alegori study: efficacy of a bevacizumab nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). A randomized trial against placebo with dose selection
Dupuis-Girod, S.
Fargeton, A-E
Paez, C.
Ambrun, A.
Decullier, E.
Roux, A.
Breant, V
Beni, K.
Riviere, S.
Lacombe, P.
Dufour, X.
Harle, J. R.
Babin, E.
Carette, M. F.
Corre, R.
Duffau, P.
Hatron, P. Y.
Kaminsky, P.
Lavigne, C.
Lorcerie, B.
Porcher, R.
Faure, F.
ANGIOGENESIS, 2015, 18 (04) : 538 - 539
[5] Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
Caraceni, T
Musicco, M
PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) : 107 - 114
[6] Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
Kim, Youjin
Lee, Su Jin
Park, Keunchil
Lee, Se-hoon
Sun, Jong Mu
Keam, Bhumsuk
An, Ho Jung
Cho, Jae Yong
Kim, Jin-Soo
Lee, Ha-young
Kim, HyeRyun
Lee, Kyoung Eun
Choi, Moon Young
Lee, Ki Hyeong
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial
D. Molina-Morant
M. L. Fernández
P. Bosch-Nicolau
E. Sulleiro
M. Bangher
F. Salvador
A. Sanchez-Montalva
A. L. P. Ribeiro
A. M. B. de Paula
S. Eloi
R. Correa-Oliveira
J. C. Villar
S. Sosa-Estani
I. Molina
Trials, 21
[8] BABH study: a double-blind, randomized national phase 3 study to evaluate efficacy and safety of bevacizumab for the treatment of severe bleedings in hemorrhagic hereditary telangiectasia (HHT)
Dupuis-Girod, S.
Saurin, J.
Philouze, P.
Decullier, E.
RiviOre, S.
Cartier, C.
Altwegg, R.
Gilbert-Dussardier, B.
Hatron, P. Y.
Mohamed, S.
Duffau, P.
Corre, R.
Leguy-Seguin, V
Chinet, T.
Lacombe, P.
Lesur, G.
Lesniak, J.
HarlO, J. R.
Carette, M. F.
Lavigne, C.
Laccourreye, L.
Oberti, F.
Grobost, V
Magro, P.
Alric, L.
Pistorius, M.
El Chehadeh, S.
Fargeton, A.
Pivot, C.
Paintaud, G.
Faure, F.
ANGIOGENESIS, 2018, 21 (01) : 134 - 134
[9] Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis
Moore, Z. R.
Rimner, A.
Lobaugh, S.
Geyer, A.
Gelblum, D. Y.
Shepherd, A. F.
Shaverdian, N.
Wu, A. J.
Chaft, J. E.
Zauderer, M. G.
Rudin, C. M.
Vander Els, N.
Chawla, M.
Jones, D. R.
Sopka, D. M.
Mak, R.
Liao, Z.
Gomez, D. R.
Zhang, Z.
Paik, P.
ANNALS OF ONCOLOGY, 2022, 33 : S118 - S118
[10] A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
Yen, Chia-Jui
Kim, Tae-You
Feng, Yin-Hsun
Chao, Yee
Lin, Deng-Yn
Ryoo, Baek-Yeol
Huang, Dennis Chin-Lun
Schnell, David
Hocke, Julia
Loembe, Arsene-Bienvenu
Cheng, Ann-Lii
LIVER CANCER, 2018, 7 (02) : 165 - 178

← 1 2 3 4 5 →